Medication administration through enteral feeding tubes

American Journal of Health-System Pharmacy

Volumn 65, Issue 24, 2008, Pages 2347-2357

  Williams, Nancy Toedter ^a  

^a SOUTHWESTERN OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

Dosage forms; Drug administration; Drug interactions; Excipients; Incompatibilities; Nutrition; Sorbitol; Toxicity

Indexed keywords

CARBAMAZEPINE; CIPROFLOXACIN; DILTIAZEM; ESOMEPRAZOLE; FERROUS SULFATE; LANSOPRAZOLE; LEVOFLOXACIN; OFLOXACIN; OMEPRAZOLE; PANTOPRAZOLE; PARACETAMOL; PHENYTOIN; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RABEPRAZOLE; SORBITOL; SUCRALFATE; VERAPAMIL; WARFARIN;

ABDOMINAL CRAMP; BEZOAR; BLOATING; DIARRHEA; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DYSPHAGIA; ELIXIR; ENTERIC FEEDING; FEEDING APPARATUS; FLATULENCE; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HUMAN; NUTRITIONAL SUPPORT; PRIORITY JOURNAL; REVIEW; SOLID; SUSPENSION; TABLET;

EID: 57649131047     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080155     Document Type: Review

References (68)

1. ASPEN Board of Directors and the Clinical Guidelines Task Force. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. JPEN J Patenter Enteral Nutr. 2002; 26(suppl 1):1SA-138SA. [Erratum, JPEN J Parenter Enteral Nutr. 2002; 26:144.]
2. Gianotti L, Alexander JW, Nelson JL et al. Role of early enteral feeding and acute starvation on postburn bacterial translocation and host defense: prospective, randomized trials. Crit Care Med. 1994; 22:265-72.
3. Marik PE, Zaloga GP. Early enteral nutrition in acutely ill patients: a systematic review. Crit Care Med. 2001; 29:2264-70. [Erratum, Crit Care Med. 2002; 30:725.]
4. Moore FA, Feliciano DV, Andrassy RJ et al. Early enteral feeding, compared with parenteral, reduces postoperative septic complications: the results of a meta-analysis. Ann Surg. 1992; 216:172-83.
5. Beckwith MC, Feddema SS, Barton RG et al. A guide to drug therapy in patients with enteral feeding tubes: dosage form selection and administration methods. Hosp Pharm. 2004; 39:225-37.
6. Kumpf VJ, Chessman KH. Enteral nutrition. In: DiPiro JT, Talbert RL, Yee GC et al., eds. Pharmacotherapy: a pathophysiologic approach. 6th ed. New York: McGraw-Hill; 2005:2615-34.
7. Minard G. Enteral access. Nutr Clin Pract. 1994; 9:172-82.
8. Marks JM, Ponsky JL. Access routes for enteral nutrition. Gastroenterologist. 1995; 3:130-40.
9. Gora ML, Tschampel MM, Visconti JA. Considerations of drug therapy in patients receiving enteral nutrition. Nutr Clin Pract. 1989; 4:105-10.
10. Magnuson BL, Clifford TM, Hoskins LA et al. Enteral nutrition and drug administration, interactions, and complications. Nutr Clin Pract. 2005; 20:618-24.
11. Lord L, Harrington M. Enteral nutrition implementation and management. In: Merritt R, DeLegge MH, Holcombe B et al., eds. The ASPEN nutrition support practice manual. 2nd ed. Silver Spring, MD: American Society for Parenteral and Enteral Nutrition; 2005:76-89.
12. Gilbar PJ. A guide to enteral drug administration in palliative care. J Pain Symptom Manage. 1999; 17:197-207.
13. Thomson FC, Naysmith MR, Lindsay A. Managing drug therapy in patients receiving enteral and parenteral nutrition. Hosp Pharmacist. 2000; 7:155-64.
14. Rollins CJ. Drug-nutrient interactions. In: Gottschlich MM, DeLegge MH, Mattox T et al, eds. The ASPEN nutrition support core curriculum: a case-based approach - the adult patient. Silver Spring, MD: American Society for Parenteral and Enteral Nutrition; 2007:340-59.
15. Varella L, Jones E, Meguid MM. Drug-nutrient interactions in enteral feeding: a primary care focus. Nurse Pract. 1997; 22:98-104.
16. Lourenco R. Enteral feeding: drug/nutrient interaction. Clin Nutr. 2001; 20:187-93.
17. Dickerson RN, Melnik G. Osmolality of oral drug solutions and suspensions. Am J Hosp Pharm. 1988; 45:832-4.
18. Dickerson RN. Medication administration considerations for patients receiving enteral tube feedings. Hosp Pharm. 2004; 39:84-9,96.
19. Nyffeler MS, Frankel E, Hayes E et al. Drug-nutrient interactions. In: Merritt R, DeLegge MH, Holcombe B et al., eds. The ASPEN nutrition support practice manual. 2nd ed. Silver Spring, MD: American Society for Parenteral and Enteral Nutrition; 2005:118-36.
20. Lutomski DM, Gora ML, Wright SM et al. Sorbitol content of selected oral liquids. Ann Pharmacother. 1993; 27:269-74.
21. Miller SJ, Oliver AD. Sorbitol content of selected sugar-free liquid medications. Hosp Pharm. 1993; 28:741-4,755.
22. Carrougher JG, Barrilleaux CN. Esophageal bezoars: the sucralith. Crit Care Med. 1991; 19:837-9.
23. Cutie AJ, Altman E, Lenkel L. Compatibility of enteral products with commonly employed drug additives. JPEN J Parenter Enteral Nutr. 1983; 7:186-91.
24. Belknap DC, Seifert CF, Petermann M. Administration of medications through enteral feeding catheters. Am J Crit Care. 1997; 6:382-92.
25. Mitchell JF. Institute for Safe Medication Practices. Oral dosage forms that should not be crushed. www.ismp.org/tools/donotcrush.pdf (accessed 2008 Mar 20).
26. Ferrone M, Raimondo M, Scolapio JS. Pancreatic enzyme pharmacotherapy. Pharmacotherapy. 2007; 27:910-20.
27. Dickerson RN, Tidwell AC, Brown RO. Adverse effects from inappropriate medication administration via a jejunostomy feeding tube. Nutr Clin Pract. 2003; 18:402-5.
28. Gilbert S, Hatton J, Magnuson B. How to minimize interaction between phenytoin and enteral feedings: two approaches. Nutr Clin Pract. 1996; 11:28-31.
29. Bauer LA. Interference of oral phenytoin absorption by continuous nasogastric feedings. Neurology. 1982; 32:570-2.
30. Au Yeung SC, Ensom MH. Phenytoin and enteral feedings: does evidence support an interaction? Ann Pharmacother. 2000; 34:896-905.
31. Krueger KA, Garnett WR, Comstock TJ et al. Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability. Epilepsia. 1987; 28:706-12.
32. Cacek AT, DeVito JM, Koonce JR. In vitro evaluation of nasogastric administration methods for phenytoin. Am J Hosp Pharm. 1986; 43:689-92.
33. Hennessy DD. Recovery of phenytoin from feeding formulas and protein mixtures. Am J Health-Syst Pharm. 2003; 60:1850-2.
34. Doak KK, Haas CE, Dunnigan KJ et al. Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings. Pharmacotherapy. 1998; 18:637-45.
35. Bass J, Miles MV, Tennison MB et al. Effects of enteral tube feeding on the absorption and pharmacokinetic profile of carbamazepine suspension. Epilepsia. 1989; 30:364-9.
36. Clark-Schmidt AL, Garnett WR, Lowe DR et al. Loss of carbamazepine suspension through nasogastric feeding tubes. Am J Hosp Pharm. 1990; 47:2034-7.
37. Riss JR, Kriel RL, Kammer NM et al. Administration of Carbatrol to children with feeding tubes. Pediatr Neurol. 2002; 27:193-5.
38. Martin JE, Lutomski DM. Warfarin resistance and enteral feedings. JPEN J Parenter Enteral Nutr. 1989; 13:206-8.
39. Penrod LE, Allen JB, Cabacungan LR. Warfarin resistance and enteral feedings: 2 case reports and a supporting in vitro study. Arch Phys Med Rehabil. 2001; 82:1270-3.
40. Dickerson RN, Garmon WM, Kuhl DA et al. Vitamin K-independent warfarin resistance after concurrent administration of warfarin and continuous enteral nutrition. Pharmacotherapy. 2008; 28:308-13.
41. Kuhn TA, Garnett WR, Wells BK et al. Recovery of warfarin from an enteral nutrient formula. Am J Hosp Pharm. 1989; 46:1395-9.
42. Nyffeler MS. Ciprofloxacin use in the enterally fed patient. Nutr Clin Pract. 1999; 14:73-7.
43. Piccolo ML, Toossi Z, Goldman M. Effect of coadministration of a nutritional supplement on ciprofloxacin absorption. Am J Hosp Pharm. 1994; 51:2697-9.
44. Mueller BA, Brierton DG, Abel SR et al. Effect of enteral feeding with Ensure on oral bioavailabilities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother. 1994; 38:2101-5.
45. Healy DP, Brodbeck MC, Clendening CE. Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. Antimicrob Agents Chemother. 1996; 40:6-10.
46. Mimoz O, Binter V, Jacolot A et al. Pharmacokinetics and absolute bioavailability of ciprofloxacin administered through a nasogastric tube with continuous enteral feeding to critically ill patients. Intensive Care Med. 1998; 24:1047-51.
47. Burkhardt O, Stass H, Thuss U et al. Effects of enteral feeding on the oral bioavailability of moxifloxacin in healthy volunteers. Clin Pharmacokinet. 2005; 44:969-76.
48. Wright DH, Pietz SL, Konstantinides FN et al. Decreased in vitro fluoroquinolone concentrations after admixture with an enteral feeding formulation. JPEN J Parenter Enteral Nutr. 2000; 24:42-8.
49. Engle KK, Hannawa TE. Techniques for administering oral medications to critical care patients receiving continuous enteral nutrition. Am J Health-Syst Pharm. 1999; 56:1441-4.
50. Prilosec (omeprazole) package insert. Wilmington, DE: AstraZeneca LP; 2007 Apr.
51. Nexium (esomeprazole) package insert. Wilmington, DE: AstraZeneca LP; 2007 Apr.
52. Prevacid (lansoprazole) package insert. Lake Forest, IL: TAP Pharmaceuticals Inc.; 2007 Jul.
53. Protonix (pantoprazole) package insert. Philadelphia, PA: Wyeth Pharmaceuticals Inc.; 2007 Dec.
54. AcipHex (rabeprazole) package insert. Woodcliff Lake, NJ: Eisai Inc.; 2007 Feb.
55. Chun AH, Shi HH, Achari R et al. Lansoprazole: administration of the contents of a capsule dosage formulation through a nasogastric tube. Clin Ther. 1996; 18:833-42.
56. Sharma VK, Peyton B, Spears T et al. Oral pharmacokinetics of omeprazole and lansoprazole after single and repeated doses as intact capsules or as suspensions in sodium bicarbonate. Aliment Pharmacol Ther. 2000; 14:887-92.
57. Dunn A, White CM, Reddy P et al. Delivery of omeprazole and lansoprazole granules through a nasogastric tube in vitro. Am J Health-Syst Pharm. 1999; 56:2327-30.
58. Phillips JO, Olsen KM, Rebuck JA et al. A randomized, pharmacokinetic and pharmacodynamic, cross-over study of duodenal or jejunal administration compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers. Am J Gastroenterol. 2001; 96:367-72. [Erratum, Am J Gastroenterol. 2001: 96:2528.
59. Zegerid (omeprazole/sodium bicarbonate) package insert. San Diego, CA: Santarus, Inc.; 2008 Jan.
60. Dentinger PJ, Swenson CF, Anaizi NH. Stability of pantoprazole in an extemporaneously compounded oral liquid. Am J Health-Syst Pharm. 2002; 59:953-6.
61. Ferron GM, Ku S, Abell M et al. Oral bioavailability of pantoprazole suspended in sodium bicarbonate solution. Am J Health-Syst Pharm. 2003; 60:1324-9.
62. Marcuard SP, Stegall KS. Unclogging feeding tubes with pancreatic enzyme. JPEN J Parenter Enteral Nutr. 1990; 14:198-200.
63. Lord LM. Restoring and maintaining patency of enteral feeding tubes. Nutr Clin Pract. 2003; 18:422-6.
64. Reising DL, Neal RS. Enteral tube flushing. Am J Nurs. 2005; 105:58-63.
65. Sriram K, Jayanthi V, Lakshmi RG et al. Prophylactic locking of enteral feeding tubes with pancreatic enzymes. JPEN J Parenter Enteral Nutr. 1997; 21:353-6.
66. Bourgault AM, Heyland DK, Drover JW et al. Prophylactic pancreatic enzymes to reduce feeding tube occlusions. Nutr Clin Pract. 2003; 18:398-401.
67. Marcuard SP, Stegall KL, Trogdon S. Clearing obstructed feeding tubes. JPEN J Parenter Enteral Nutr. 1989; 13:81-3.
68. Clog Zapper package insert. Wheeling, IL: Corpak Medsystems; 1996.